Cargando…
miR-34 – a microRNA replacement therapy is headed to the clinic
MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are necessary for basic cancer cell viability a...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387671/ https://www.ncbi.nlm.nih.gov/pubmed/22783274 http://dx.doi.org/10.3389/fgene.2012.00120 |
_version_ | 1782237117778231296 |
---|---|
author | Bader, Andreas G. |
author_facet | Bader, Andreas G. |
author_sort | Bader, Andreas G. |
collection | PubMed |
description | MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. This broad anti-oncogenic activity holds the prospect of creating a new remedy that is effective against tumor heterogeneity. This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a miR-34 therapy that may be among the first miRNA mimics to reach the clinic. |
format | Online Article Text |
id | pubmed-3387671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Frontiers Research Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33876712012-07-10 miR-34 – a microRNA replacement therapy is headed to the clinic Bader, Andreas G. Front Genet Genetics MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. This broad anti-oncogenic activity holds the prospect of creating a new remedy that is effective against tumor heterogeneity. This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a miR-34 therapy that may be among the first miRNA mimics to reach the clinic. Frontiers Research Foundation 2012-07-02 /pmc/articles/PMC3387671/ /pubmed/22783274 http://dx.doi.org/10.3389/fgene.2012.00120 Text en Copyright © Bader. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) , which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited. |
spellingShingle | Genetics Bader, Andreas G. miR-34 – a microRNA replacement therapy is headed to the clinic |
title | miR-34 – a microRNA replacement therapy is headed to the clinic |
title_full | miR-34 – a microRNA replacement therapy is headed to the clinic |
title_fullStr | miR-34 – a microRNA replacement therapy is headed to the clinic |
title_full_unstemmed | miR-34 – a microRNA replacement therapy is headed to the clinic |
title_short | miR-34 – a microRNA replacement therapy is headed to the clinic |
title_sort | mir-34 – a microrna replacement therapy is headed to the clinic |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387671/ https://www.ncbi.nlm.nih.gov/pubmed/22783274 http://dx.doi.org/10.3389/fgene.2012.00120 |
work_keys_str_mv | AT baderandreasg mir34amicrornareplacementtherapyisheadedtotheclinic |